Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.
Cancer Biol Ther. 2016 Apr 22;:0
Authors: Mahmoud F, Shields B, Makhoul I, Hutchins LF, Shalin SC, Tackett AJ
Abstract
There is accumulating evidence that the histone methyltransferase enhancer of zeste homologue 2 (EZH2), the main component of the polycomb-repressive complex 2 (PRC2), is involved in melanoma progression and metastasis. Novel drugs that target and reverse such epigenetic changes may find a way into the management of patients with advanced melanoma. We provide a comprehensive up-to-date review of the role and biology of EZH2 on gene transcription, senescence/apoptosis, melanoma microenvironment, melanocyte stem cells, the immune system, and micro RNA. Furthermore, we discuss EZH2 inhibitors as potential anti-cancer therapy.
PMID: 27105109 [PubMed - as supplied by publisher]
from Cancer via ola Kala on Inoreader http://ift.tt/1ps7Anv
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου